Novel CB1/CB2 receptor partial agonist (Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively). Orally active CB1 agonist in vivo. Displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain.